Targeted delivery of anti-CSF1R antibodies to joints with tenosynovial giant cell tumors
US11752096B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 22, 2022 |
| Grant date | Sep 12, 2023 |
| Priority date | — |
| Expiry date | Aug 22, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/90
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a tissue that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.